CVRX

CVRx, Inc. (CVRX) | Rumor.io

CVRx

CVRX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,354

Bullish sentiment (50-day avg)82%

Price to earnings ratio-1.27

Market capitalization69M

Earnings per share-1.97

Dividend yield (TTM)—

Revenue (annual)56.7M

Net income (annual)-53.3M

Social

What share of all stock conversation is about CVRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 11

CVRx, Inc. announced the termination of its Chief Revenue Officer, Robert John, and the assumption of the Interim Head of Sales role by Paul Verrastro, who has over 30 years of medical device sales experience.
The company's revised commercial outlook and need for improved commercial execution led to the change in sales leadership, with Kevin Hykes, President and CEO, expressing confidence in Verrastro's ability to lead the sales team.
Following the management change, some investors are optimistic about the stock's potential, with a few suggesting buying on any selling pressure and others predicting a bounce to $3.00 fairly quickly.

Generated by AI

Sentiment

Of the messages about CVRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0% -82.35	90.81% -1.38
Bearish	—	100%	100% +82.35	9.19% +1.38

Bullish· Apr 8

CVRx, Inc. has a strong cash position of $102.7 million, providing a solid foundation for future growth.
The company's revenue growth of 15% year-over-year to $12.3 million, and increased active plant centers, are positive indicators of its business performance.
Analysts such as Cantor Fitzgerald and Lake Street have reaffirmed their bullish stance on CVRx, Inc. with Overweight and Buy ratings, respectively, and target prices of $20.00 and $19.00.

Bearish· Aug 7

The company's CEO is described as "trash" and the CFO is said to be incompetent, suggesting a lack of leadership.
The company's sales execution is a major problem, with revenue growth but a slashed full-year outlook, indicating that the company is struggling to meet its sales targets.
The company is heavily shorted, with no covering yet, and there are concerns about the sustainability of its path forward as an independent company, suggesting a high risk of further decline.

Generated by AI

Topics

Of the messages about CVRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	84.62%	34.5%
Analysts	—	0%	15.38%	24.89%
Earnings	—	0%	0%	3.49%
Technical Analysis	—	0%	0%	35.81%
Controversies	—	0%	0%	1.31%
Macro	—	0%	0%	0%

Analysts· Jul 26

Canaccord Genuity initiated coverage of CVRx with a "buy" rating and price target of $30.
William Blair initiated coverage on CVRx with a rating of outperform, while JPMorgan Chase & Co. and Piper Sandler initiated coverage with overweight ratings of $24 and $26, respectively.
Analysts from Canaccord Genuity, William Blair, JPMorgan Chase & Co., and Piper Sandler have initiated coverage on CVRx with various ratings and price targets, including buy, outperform, and overweight.

Announcements· Feb 22

CVRx's Barostim is the first medical technology approved by FDA to use neuromodulation to improve symptoms of heart failure patients.
Barostim received FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S.
Barostim has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area.

Generated by AI

Community

Of the messages about CVRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	1.82%	2.9%	26.84%
Newcomers	—	98.18%	97.1%	73.16%

Regulars· Aug 7

The regulars are focused on CVRx's recent Q2 loss and revenue growth, with some noting a 16% revenue increase despite lowered full-year outlook due to sales challenges.
The hiring of new staff, including a CFO, is seen as a sign of trouble ahead, with one participant suggesting that the company is hiring because things are so terrible.
The regulars are concerned about the company's ability to execute its plans, with one participant suggesting that the company is on an "unsustainable path forward as an independent company" and may be preparing for a "fire sale of assets".

Newcomers· Aug 11

The new interim head of sales, Paul Verrastro, has over 30 years of experience in medical device sales and marketing, and will lead the sales organization while the company searches for a permanent successor.
The company has revised its commercial outlook and needs to improve commercial execution, leading to a change in sales leadership, with Kevin Hykes, President and CEO, expressing confidence in Verrastro's ability to lead the sales team.
The stock price may bounce back to $3.00 fairly quickly, and some analysts are optimistic about the company's prospects, with one user suggesting a buy on any selling pressure and another thinking the stock has bottomed out.

Generated by AI

Landry Brings Two Decades of Medtech and Public Company Finance ExperienceMINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will

8d agoYahoo Finance

CVRx Secures Devoted Health Coverage for Barostim Therapy

CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.

1mo agoYahoo Finance

CVRx responds to shareholder letter on company valuation

1mo agoInvesting.com

Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com

1mo agoInvesting.com

Also Discussed

Investors talking about CVRX also mention

#	Name	Attention
1	SCPH - scPharmaceuticals Inc.	——
2	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
3	Sana Biotechnology Inc.SANA	0%0
4	TransMedics Group, Inc.TMDX	0%-0.01
5	NARI - Inari Medical, Inc.	——
6	Swvl Holdings Corp Class A Common SharesSWVL	0%0
7	SWAV - ShockWave Medical, Inc.	——
8	TRML - Tourmaline Bio, Inc.	——
9	Verra Mobility Corp. Class A Common StockVRRM	0%0
10	Globant S.A.GLOB	0%0

CVRx, Inc.

Healthcare
Medical Devices

CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease. Its flagship product, Barostim, is an implantable therapy system that delivers electrical pulses to carotid baroreceptors to help regulate autonomic nervous system activity and support cardiovascular function. The company’s current offerings center on Baroreflex Activation Therapy, a minimally invasive treatment approach used for patients with heart failure and other cardiovascular conditions. CVRx develops, manufactures, and commercializes its products in the United States, Germany, and selected international markets through direct sales and distribution channels. Headquartered in Minneapolis, Minnesota, CVRx plays a specialized role in the medical technology market by providing device-based therapies that address complex cardiac care needs.

Website

Location

9201 West Broadway Avenue

Minneapolis, MN, 55445

United States

Social

What share of all stock conversation is about CVRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 11

CVRx, Inc. announced the termination of its Chief Revenue Officer, Robert John, and the assumption of the Interim Head of Sales role by Paul Verrastro, who has over 30 years of medical device sales experience.
The company's revised commercial outlook and need for improved commercial execution led to the change in sales leadership, with Kevin Hykes, President and CEO, expressing confidence in Verrastro's ability to lead the sales team.
Following the management change, some investors are optimistic about the stock's potential, with a few suggesting buying on any selling pressure and others predicting a bounce to $3.00 fairly quickly.

Generated by AI

Sentiment

Of the messages about CVRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0% -82.35	90.81% -1.38
Bearish	—	100%	100% +82.35	9.19% +1.38

Bullish· Apr 8

CVRx, Inc. has a strong cash position of $102.7 million, providing a solid foundation for future growth.
The company's revenue growth of 15% year-over-year to $12.3 million, and increased active plant centers, are positive indicators of its business performance.
Analysts such as Cantor Fitzgerald and Lake Street have reaffirmed their bullish stance on CVRx, Inc. with Overweight and Buy ratings, respectively, and target prices of $20.00 and $19.00.

Bearish· Aug 7

The company's CEO is described as "trash" and the CFO is said to be incompetent, suggesting a lack of leadership.
The company's sales execution is a major problem, with revenue growth but a slashed full-year outlook, indicating that the company is struggling to meet its sales targets.
The company is heavily shorted, with no covering yet, and there are concerns about the sustainability of its path forward as an independent company, suggesting a high risk of further decline.

Generated by AI

Topics

Of the messages about CVRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	84.62%	34.5%
Analysts	—	0%	15.38%	24.89%
Earnings	—	0%	0%	3.49%
Technical Analysis	—	0%	0%	35.81%
Controversies	—	0%	0%	1.31%
Macro	—	0%	0%	0%

Analysts· Jul 26

Canaccord Genuity initiated coverage of CVRx with a "buy" rating and price target of $30.
William Blair initiated coverage on CVRx with a rating of outperform, while JPMorgan Chase & Co. and Piper Sandler initiated coverage with overweight ratings of $24 and $26, respectively.
Analysts from Canaccord Genuity, William Blair, JPMorgan Chase & Co., and Piper Sandler have initiated coverage on CVRx with various ratings and price targets, including buy, outperform, and overweight.

Announcements· Feb 22

CVRx's Barostim is the first medical technology approved by FDA to use neuromodulation to improve symptoms of heart failure patients.
Barostim received FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S.
Barostim has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area.

Generated by AI

Community

Of the messages about CVRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	1.82%	2.9%	26.84%
Newcomers	—	98.18%	97.1%	73.16%

Regulars· Aug 7

The regulars are focused on CVRx's recent Q2 loss and revenue growth, with some noting a 16% revenue increase despite lowered full-year outlook due to sales challenges.
The hiring of new staff, including a CFO, is seen as a sign of trouble ahead, with one participant suggesting that the company is hiring because things are so terrible.
The regulars are concerned about the company's ability to execute its plans, with one participant suggesting that the company is on an "unsustainable path forward as an independent company" and may be preparing for a "fire sale of assets".

Newcomers· Aug 11

The new interim head of sales, Paul Verrastro, has over 30 years of experience in medical device sales and marketing, and will lead the sales organization while the company searches for a permanent successor.
The company has revised its commercial outlook and needs to improve commercial execution, leading to a change in sales leadership, with Kevin Hykes, President and CEO, expressing confidence in Verrastro's ability to lead the sales team.
The stock price may bounce back to $3.00 fairly quickly, and some analysts are optimistic about the company's prospects, with one user suggesting a buy on any selling pressure and another thinking the stock has bottomed out.

Generated by AI

CVRx

Social

Aug 11

Bullish· Apr 8

Bearish· Aug 7

Analysts· Jul 26

Announcements· Feb 22

Regulars· Aug 7

Newcomers· Aug 11

Canaccord reiterates CVRx stock Buy rating after CFO appointment

CVRx Names New Chief Financial Officer

CVRx Appoints John Landry as Chief Financial Officer

CVRx Secures Devoted Health Coverage for Barostim Therapy

CVRx responds to shareholder letter on company valuation

Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com

Also Discussed

CVRx, Inc.

Company Information

Location

Social

Aug 11

Bullish· Apr 8

Bearish· Aug 7

Analysts· Jul 26

Announcements· Feb 22

Regulars· Aug 7

Newcomers· Aug 11

Canaccord reiterates CVRx stock Buy rating after CFO appointment

CVRx Names New Chief Financial Officer

CVRx Appoints John Landry as Chief Financial Officer

CVRx Secures Devoted Health Coverage for Barostim Therapy

CVRx responds to shareholder letter on company valuation

Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com

Also Discussed